|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
207 Trials |
|
10745 News |
|
| «12...124125126127128129130131132133134...136137» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Editors' note: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis. (Pubmed Central) - Jul 25, 2019
No abstract available
- | Clinical, Journal: Decreased Expression of Circulating Aire and Increased Tfh/Tfr cells in myasthenia gravis patients. (Pubmed Central) - Jul 24, 2019
However, no significant relation was manifestated in our study between the subset age of MG and Aire level. Overall, these findings imply circulating Aire might play a role in the imbalance of cTfh and cTfr cells and participate in the pathogenesis of MG.
- | Journal: Upper Eyelid Blepharoplasty: A Novel Method to Predict and Improve Outcomes. (Pubmed Central) - Jul 24, 2019
This equation was extrapolated with regression analysis: Change in MFD = -0.40 + (-0.28xChangeVSD) + (0.53xChangeMCD) with |R|=0.28. In order to better predict and obtain desired upper eyelid blepharoplasty outcomes, an equation has been created.
- | prednisolone / generics
Journal: Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. (Pubmed Central) - Jul 24, 2019
In order to better predict and obtain desired upper eyelid blepharoplasty outcomes, an equation has been created. Our scoring system based on three clinical characteristics can predict the likelihood of steroid-induced initial worsening in MG.
- | tacrolimus / generics
Clinical, Journal: Ocular myasthenia gravis patients following the administration of tacrolimus and steroids. (Pubmed Central) - Jul 24, 2019
Our scoring system based on three clinical characteristics can predict the likelihood of steroid-induced initial worsening in MG. No abstract available
- | Clinical, Journal: Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer. (Pubmed Central) - Jul 23, 2019
According to their survival time, SCLC patients with LEMS showed a more favorable prognosis than those without LEMS. In the time of follow-up, most NT-LEMS showed improvement or obtained status of CSR/PR/MM after immunosuppressive therapy and no significant difference in proportion of achieving CSR/PR/MM was found between SCLC-LEMS and NT-LEMS patients (0/5 vs 6/13, p = 0.114).
- | Journal, IO Biomarker: Association of CTLA-4 polymorphisms with increased risks of myasthenia gravis. (Pubmed Central) - Jul 19, 2019
A total of 1460 cases and 1652 controls from 12 studies were enrolled in the analysis. Our results indicated that rs231775 and rs733618 were associated with higher risks of MG, providing potential references for future case-control studies.
- | Lorbrena (lorlatinib) / Pfizer
Clinical, Journal: New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent. (Pubmed Central) - Jul 19, 2019
Our results indicated that rs231775 and rs733618 were associated with higher risks of MG, providing potential references for future case-control studies. No abstract available
- | Clinical, Journal: Sleep evaluation in patients with myasthenia gravis. (Pubmed Central) - Jul 19, 2019
No abstract available No abstract available
- | Clinical, Journal: Hypophonia as only presenting symptom in myasthenia gravis - a diagnostic dilemma in poor countries: a case report. (Pubmed Central) - Jul 19, 2019
Relevant laboratory tests and clinical examinations are important to diagnose this disease properly. In resources-deprived nations like Nepal, where several investigations are expensive and access to them is difficult, it becomes very difficult to achieve a solid diagnosis for rare presentations of diseases.
- | Clinical, Journal: An ocular myasthenia gravis attack after oral pyrantel pamoate: An unusual case report. (Pubmed Central) - Jul 18, 2019
Pyrantel is an antihelminthic that acts as an agonist of nicotinic acetylcholine receptors (AChRs) of nematodes and exerts its therapeutic effects by depolarizing their muscle membranes. Consequently, there may be an association between pyrantel pamoate and MG.
- | Journal: Myasthenia gravis: an icy diagnosis. (Pubmed Central) - Jul 18, 2019
Consequently, there may be an association between pyrantel pamoate and MG. No abstract available
- | NN1213 / Novo Nordisk
Biomarker, Trial completion, Trial completion date: Biomarkers in Neural Disorders (clinicaltrials.gov) - Jul 18, 2019
P=N/A, N=54, Completed, Sponsor: University of Pennsylvania
No abstract available Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jul 2019
- | Journal: Late onset myasthenia gravis and carcinoid tumour: paraneoplastic syndrome? (Pubmed Central) - Jul 17, 2019
Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jul 2019 No abstract available
- | Soliris (eculizumab) / AstraZeneca
Trial completion, Trial completion date, Trial primary completion date: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 16, 2019
P3, N=117, Completed, Sponsor: Alexion Pharmaceuticals
No abstract available Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Mar 2019 | Trial primary completion date: Jan 2020 --> Mar 2019
- | Retrospective data, Journal: Single-center retrospective analysis of 162 cases with thymoma complicating myasthenia gravis. (Pubmed Central) - Jul 13, 2019
The pathology type and clinical stages of thymoma complicating myasthenia gravis are related to the types of myasthenia gravis and the myasthenic crisis during perioperative period. Therefore, our results indicate that the thoracoscope treatment is safe and effective.
- | Journal: Rating Scale for Ocular Myasthenia Gravis: A Call to Action! (Pubmed Central) - Jul 13, 2019
Therefore, our results indicate that the thoracoscope treatment is safe and effective. No abstract available
- | Journal: Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. (Pubmed Central) - Jul 13, 2019
Robotic thymectomy is a technically feasible and safe operation with a low morbidity and short hospitalization. It is associated with good neurological long-term results in terms of both CSR and clinical improvement.
- | Journal: Residua of thymus in the mediastinum - clinical aspects - cadaveric study. (Pubmed Central) - Jul 11, 2019
The remnants of the thymic tissue were found in 61 out of 100 specimens studied. It means that residua of ectopic thymic tissue is common, which may have a huge impact on the results of treatment of many diseases i.e. myasthenia gravis in course of thymoma.
- | Review, Journal: Autologous haematopoietic stem cell transplantation for neurological diseases. (Pubmed Central) - Jul 11, 2019
A smaller number of patients with other neuroinflammatory conditions have been treated with promising results. Herein, current data on clinical effect and safety of autologous haematopoietic stem cell transplantation for neurological disease are reviewed.
- | Journal: Non-motor Comorbidity of Myasthenia Gravis: Myasthenia Gravis as a Systemic Immunological Disorder Involving Non-motor Systems. (Pubmed Central) - Jul 11, 2019
In both cases, autoreactive T lymphocytes inappropriately stimulated by thymus tissue may have played key roles in generating the various autoimmune-associated symptoms. Consequently, systemic immunological involvement due to the thymoma-associated breakdown of immunoregulations in both motor and non-motor systems should be considered in MG patients.
- | Clinical, Journal, HEOR: Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. (Pubmed Central) - Jul 10, 2019
Consequently, systemic immunological involvement due to the thymoma-associated breakdown of immunoregulations in both motor and non-motor systems should be considered in MG patients. Refractory MG is associated with higher disease burden and healthcare utilization than nonrefractory MG.
- |||||| Rystiggo (rozanolixizumab-noli) / UCB
Enrollment open: A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 7, 2019
P3, N=240, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Refractory MG is associated with higher disease burden and healthcare utilization than nonrefractory MG. Not yet recruiting --> Recruiting
- | Journal: Neuromuscular Junction Formation, Aging, and Disorders. (Pubmed Central) - Jul 7, 2019
Expected final online publication date for the Annual Review of Physiology Volume 80 is February 10, 2018. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
- | Rituxan (rituximab) / Roche, Biogen
Journal: Myastenia and small doses of ionizing radiation: experience of successful use of rituximab for treatment of an irradiated with myasthenia gravis. (Pubmed Central) - Jul 7, 2019
The positive effect was marked in the nearest and remote peri ods. Taking to account the efficacy, safety and good tolerability of rituximab, it is advisable to recommend treat ment for people exposed to ionizing radiation and developing myasthenia associated with chronic mixed infection by Toxoplasma, Epstein Barr, Cytomegalovirus and Herpes simplex virus.
- | hydroxychloroquine / VG Lifesciences
Journal: Neuromuscular transmission defects in myopathies: rare but worth searching for. (Pubmed Central) - Jul 6, 2019
Taking to account the efficacy, safety and good tolerability of rituximab, it is advisable to recommend treat ment for people exposed to ionizing radiation and developing myasthenia associated with chronic mixed infection by Toxoplasma, Epstein Barr, Cytomegalovirus and Herpes simplex virus. Despite the rare occurrence of decrement in myopathy, its presence may urge consideration of pharmacological intervention.
- | Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. (Pubmed Central) - Jul 6, 2019
Despite the rare occurrence of decrement in myopathy, its presence may urge consideration of pharmacological intervention. Thymectomy was not associated with additional clinical improvement in this multi-center cohort of MuSK-MG patients.
- | Journal: Pregnancy-associated respiratory failure in MuSK congenital myasthenic syndrome. (Pubmed Central) - Jul 6, 2019
Thymectomy was not associated with additional clinical improvement in this multi-center cohort of MuSK-MG patients. No abstract available
- | tacrolimus / generics
Retrospective data, Review, Journal: Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis. (Pubmed Central) - Jul 6, 2019
Adverse events (AEs) were recorded in 258 of 633 patients (40.8%) with tacrolimus therapy while most were mild. Our meta-analysis demonstrates that tacrolimus may be a beneficial drug option to treat MG.
- | Review, Journal: Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. (Pubmed Central) - Jul 6, 2019
In this review, we give an overview of the history and clinical aspects of MG, with a focus on the structure and function of myasthenic autoantigens at the NMJ and how they are affected by the autoantibodies' pathogenic mechanisms. Furthermore, we give a short overview of the cells that are implicated in the production of the autoantibodies and briefly discuss diagnostic challenges and treatment strategies.
- | Preclinical, Journal: Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. (Pubmed Central) - Jul 5, 2019
Finally, we showed that the underlying mechanisms involved (a) the inhibition of cell proliferation, (b) the inhibition of B cell-related and costimulatory molecules, and (c) the activation of the complement regulator DAF/CD55. In conclusion, this study shows that a preconditioning step promotes the therapeutic effects of MSCs via combined mechanisms, making cMSCs a promising strategy for treating MG and potentially other autoimmune diseases.
- | Journal: Stiff-person syndrome after thymectomy in myasthenia gravis mimicking a post-thymectomy myasthenic crisis. (Pubmed Central) - Jul 5, 2019
In conclusion, this study shows that a preconditioning step promotes the therapeutic effects of MSCs via combined mechanisms, making cMSCs a promising strategy for treating MG and potentially other autoimmune diseases. No abstract available
- | Journal: Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. (Pubmed Central) - Jul 4, 2019
The severity of disease at entry, presence of AchRabs, thymic pathology, and duration of the disease predict a higher risk for death. Systemic illnesses including stroke, COPD, diabetes mellitus, atrial fibrillation, hyperlipidemia, myocardial infarction, and malignant tumor, which may also increase the risk of death, should be carefully monitored and managed.
- | Clinical, Journal: Pyridostigmine-Induced Bradycardia in Patient With MuSK-Ab-Positive Myasthenia Gravis and Alopecia Universalis. (Pubmed Central) - Jul 4, 2019
Systemic illnesses including stroke, COPD, diabetes mellitus, atrial fibrillation, hyperlipidemia, myocardial infarction, and malignant tumor, which may also increase the risk of death, should be carefully monitored and managed. No abstract available
- | Clinical, Journal: Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. (Pubmed Central) - Jul 4, 2019
However, mAb 131 did not reduce fetal AChR ion channel currents in electrophysiological experiments. These results indicate that mAb 131, although generated from an MG patient, is unlikely to be pathogenic and may make it a potentially useful reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita which can be caused by fetal-specific AChR-blocking autoantibodies.
- | Journal: Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions. (Pubmed Central) - Jul 4, 2019
While efficient drug-based treatments are already available to improve neuromuscular transmission for most forms of CMS, others, as well as neurological and muscular comorbidities, remain resistant. Taken together, the available pathological data point to physiological issues which remain to be understood in order to achieve precision medicine with efficient therapeutics for all individuals suffering from CMS.
- | Tirosint (levothyroxine) / IBSA Institute Biochemical SA
Journal: Myxedema Coma due to Hashimoto Thyroiditis: A Rare but Real Presentation of Failure to Thrive in Infancy. (Pubmed Central) - Jul 4, 2019
MC may be a cause of altered mental status in infancy and may simultaneously be associated with FTT on presentation. With the presence of a normal thyroid NBS, autoimmunity should be entertained as the etiology of profound hypothyroidism, as positive thyroid antibodies may prompt an exploration for coexisting diseases which may explain other presenting features.
- | Journal: Juvenile Ocular Myasthenia Gravis: Presentation and Outcome of a Large Cohort. (Pubmed Central) - Jul 4, 2019
In contrast with adults, a much lower proportion of children converted to generalized MG. This may explain the higher prevalence of isolated ocular MG among the juvenile population.
- ||| Clinical: Is the co-occurrence of multiple sclerosis and myasthenia gravis a coincidence or due to common underlying mechanisms? I have seen two patients in my career with both conditions suggesting the former. #NeuroSpeak https://t.co/j84qvzx4yI (Twitter) - Jul 3, 2019
- | Clinical, Journal: Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy. (Pubmed Central) - Jul 1, 2019
This may explain the higher prevalence of isolated ocular MG among the juvenile population. No abstract available
- | Clinical, Journal: Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis. (Pubmed Central) - Jun 30, 2019
No significant difference was observed in the rate of relapse after pharmacological remission between the thymectomy (16.7%) and medical treatment groups (21.4%). In conclusion, thymectomy may have a beneficial effect in elderly patients with non-thymomatous generalized MG.
- | Clinical, Journal: Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. (Pubmed Central) - Jun 30, 2019
TMG patients reach higher clinical severity and higher antibody titers than NTMG patients. Moreover, TMG and LO-NTMG with anti-AChR Ab differ in their HLA-DQ association, providing further evidence that these two forms may have different etiologic mechanisms.
- | Clinical, Journal: Isolated bilateral abducens paralysis without ptosis in an anti-LDL receptor-related protein 4 antibody-positive patient treated effectively with steroid-pulse therapy. (Pubmed Central) - Jun 28, 2019
Moreover, TMG and LO-NTMG with anti-AChR Ab differ in their HLA-DQ association, providing further evidence that these two forms may have different etiologic mechanisms. No abstract available
- | Clinical, Journal: A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences. (Pubmed Central) - Jun 28, 2019
The clinical features of patients with IOMG differed between genders in the rates of positive anti-AChR, follicular hyperplasia of the thymus and comorbidity with autoimmune diseases. This may suggest a different gender-based mechanism of immune intolerance towards AChR and other antigens.
- | Journal: Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis. (Pubmed Central) - Jun 28, 2019
In immunohistochemistry and immunofluorescence assays, a substantial number of CD4/Bcl-6 T cells and a greater number of larger germinal centers were observed in lymph node tissues resected from EAMG rats. Based on these results, we hypothesize that an AChR-specific Tfh cell-mediated humoral immune response contributes to the development of EAMG.
- | Soliris (eculizumab) / Alexion Pharma
Biomarker, Journal: Neurology (Pubmed Central) - Jun 26, 2019
The use of levodopa-carbidopa intestinal gel and a subcutaneous apomorphine infusion allow a reduction of motor fluctuations in Parkinson's disease. Eculizumab appears as an alternative treatment in severe forms of myasthenia gravis.
- | Clinical, Review, Journal: Clinical features of laryngeal myasthenia gravis: A case series. (Pubmed Central) - Jun 23, 2019
Fluctuation in severity of disease by neostigmine/edrophonium test is a typical feature for MG patients. AChR antibody and RNS tests should be included to evaluate the pathologic changes in the neuromuscular junction.
- | Journal: Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution. (Pubmed Central) - Jun 22, 2019
No significant differences in antibody titers were seen between the autoimmune and non-autoimmune groups. These findings support the notions that: (a) elevated VGCC-Ab titers without clinical correlation must be interpreted with caution, and (b) the clinical and electrodiagnostic criteria for LEMS should remain the mainstay in the diagnosis of LEMS.
- | Journal: Functional Exercise Capacity Evaluated by Timed Walk Tests in Myasthenia Gravis. (Pubmed Central) - Jun 22, 2019
These findings support the notions that: (a) elevated VGCC-Ab titers without clinical correlation must be interpreted with caution, and (b) the clinical and electrodiagnostic criteria for LEMS should remain the mainstay in the diagnosis of LEMS. The 6mWT and 2mWT have excellent test-retest reliability as well as moderate construct validity for the evaluation of MG patients' functional exercise capacity.
- | Clinical, Journal: Muscle weakness and functional disability in patients with myasthenia gravis. (Pubmed Central) - Jun 22, 2019
MG patients have moderately reduced isometric muscle strength and impaired physical performance. Muscle weakness and functional tests relate closely to MG-specific scales suggesting that dynamometry and functional tests can be used to monitor MG patients and as efficacy parameters in clinical trials.